Fezolinetant

Fezolinetant
	Above: molecular structure of fezolinetant Below: 3D representation of a fezolinetant molecule
Clinical data
Trade names	Veozah, Veoza
Other names	ESN-364
AHFS/Drugs.com	Monograph
MedlinePlus	a623051
License data	US DailyMed: Fezolinetant;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	G02CX06 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	51%
Metabolism	CYP1A2, (CYP2C9, CYP2C19 to lesser extent)
Metabolites	ES259564
Elimination half-life	9.6h
Excretion	Urine 76.9%, feces 14.7%
Identifiers
	IUPAC name (4-fluorophenyl)-[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone;
CAS Number	1629229-37-3;
PubChem CID	117604931;
DrugBank	DB15669;
ChemSpider	58828046;
UNII	83VNE45KXX;
KEGG	D11976;
ChEBI	CHEBI:229236;
ChEMBL	ChEMBL3608680;
CompTox Dashboard (EPA)	DTXSID601103615 ;
Chemical and physical data
Formula	C16H15FN6OS
Molar mass	358.40 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C;
	InChI InChI=1S/C16H15FN6OS/c1-9-13-19-20-14(15-18-10(2)21-25-15)23(13)8-7-22(9)16(24)11-3-5-12(17)6-4-11/h3-6,9H,7-8H2,1-2H3/t9-/m1/s1; Key:PPSNFPASKFYPMN-SECBINFHSA-N;

Fezolinetant, sold under the brand name Veozah, among others, is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause. It is a small-molecule, selective neurokinin-3 (NK₃) receptor antagonist taken by mouth. It was developed by Astellas Pharma, which acquired it from Ogeda (formerly Euroscreen) in April 2017.

The most common side effects of fezolinetant include abdominal pain, diarrhea, insomnia, back pain, hot flush, and elevated hepatic transaminases.

Fezolinetant was approved for medical use in the United States in May 2023, and it was approved in the European Union in December 2023. Fezolinetant is the first NK₃ receptor antagonist approved by the US Food and Drug Administration (FDA) to treat moderate to severe hot flashes from menopause. The FDA considers it to be a first-in-class medication.